Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.490
+0.030 (2.05%)
Jun 12, 2025, 11:23 AM - Market open
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
171
Market Cap
91.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PLRX News
- 21 days ago - Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewsWire
- 4 weeks ago - Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewsWire
- 2 months ago - Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference - GlobeNewsWire
- 2 months ago - Pliant Therapeutics: An Activist On Deck - Seeking Alpha
- 3 months ago - Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - GlobeNewsWire
- 3 months ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PRNewsWire
- 3 months ago - Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - GlobeNewsWire